Landos Biopharma, Inc. Common Stock
LABP
LABP was delisted on the 23rd of May, 2024.
45 hedge funds and large institutions have $35.3M invested in Landos Biopharma, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 12 increasing their positions, 13 reducing their positions, and 3 closing their positions.
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
13% more funds holding
Funds holding: 40 → 45 (+5)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 13
2.59% less ownership
Funds ownership: 62% → 59.41% (-2.6%)
71% less capital invested
Capital invested by funds: $120M → $35.3M (-$84.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$431K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$404K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$404K |
| 4 |
Millennium Management
New York
|
+$155K |
| 5 |
BlackRock
New York
|
+$127K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$6.6M |
| 2 |
Morgan Stanley
New York
|
-$373K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$371K |
| 4 |
JF
Jump Financial
Chicago,
Illinois
|
-$73K |
| 5 |
Walleye Capital
New York
|
-$29.7K |
LABP Hedge Fund Activity: Q1 2022 in Review
45 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Landos Biopharma, Inc. Common Stock (LABP) for Q1 2022, worth a combined $35.3M — down 71% from $120M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new LABP positions and 3 closed out — a net gain of 6 holders — while 12 added to existing stakes and 13 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $431K. The largest seller was Logos Global Management, exiting entirely with an estimated $6.6M sold.
- 45 institutional investors held Landos Biopharma, Inc. Common Stock (LABP) as of Q1 2022, up from 40 in Q4 2021.
- Funds reported $35.3M of Landos Biopharma, Inc. Common Stock stock for Q1 2022, down 71% quarter-over-quarter.
- 9 funds opened new Landos Biopharma, Inc. Common Stock positions in Q1 2022 and 3 closed out, a net change of +6 holders.
- The largest Landos Biopharma, Inc. Common Stock buyer in Q1 2022 was Renaissance Technologies, an estimated $431K added.
- The largest Landos Biopharma, Inc. Common Stock seller in Q1 2022 was Logos Global Management, an estimated $6.6M sold.
Based on aggregated 13F filings for Q1 2022.